🇺🇸 FDA
Pipeline program

Truxima 500 mg concentrate for solution for infusion, Cyclophosphamide Injection 500 mg., Epcoritamab (GEN3013), Vincristine Sulfate 1 mg/ml solution for injection, Doxorubicinhydrochlorid Bendalis 2 mg/ml Injektionslösung, Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, Prednisone Zentiva 5 mg compresse

M20-621

Phase 3 small_molecule active

Quick answer

Truxima 500 mg concentrate for solution for infusion, Cyclophosphamide Injection 500 mg., Epcoritamab (GEN3013), Vincristine Sulfate 1 mg/ml solution for injection, Doxorubicinhydrochlorid Bendalis 2 mg/ml Injektionslösung, Epcoritamab (GEN3013), Truxima 100 mg concentrate for solution for infusion, Prednisone Zentiva 5 mg compresse for Diffuse Large B-Cell Lymphoma (DLBCL) is a Phase 3 program (small_molecule) at AbbVie Deutschland GmbH & Co. KG with 1 ClinicalTrials.gov record(s).

Program details

Company
AbbVie Deutschland GmbH & Co. KG
Indication
Diffuse Large B-Cell Lymphoma (DLBCL)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials